Top Markets
#1 Black Phoenix Black Phoenix +354.79%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +76.58%
#4 Gold Park Gold Park +61.59%
#5 OpenEden OpenEden +47.95%
#6 Acurast Acurast +32.33%
#7 BasedHype BasedHype +27.12%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +20.48%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Classement en actions #40468
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Prix de l'action
$0.00204105
Capitalisation boursière
$138.92K
Changement (1 jour)
5.63%
Changement (1 an)
-60.44%
Pays
GB
Échange Solvonis Therapeutics plc (SVNS)

Catégorie

Industrials
Bénéfices pour Solvonis Therapeutics plc (SVNS)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Solvonis Therapeutics plc, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Solvonis Therapeutics plc de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Lam Research Corp. R Lam Research Corp. R
Lam Research Corp. R
LAR0.DE
- -
US
Siemens AG Siemens AG
Siemens AG
SIE.DE
$13.14B -
DE
Schneider Electric S.E. Schneider Electric S.E.
Schneider Electric S.E.
SU.PA
- -
FR
Siemens Energy AG Siemens Energy AG
Siemens Energy AG
ENR.DE
- -
DE
Parker-Hannifin Corporation Parker-Hannifin Corporation
Parker-Hannifin Corporation
PH.US
$4.56B -
US